LOGO
LOGO

Anxious Times Ahead: MNMD's Pipeline Nears Its Make-or-Break Test In 2026

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
mindmedicine 18112025 lt

Mind Medicine Inc. (MNMD) is entering a period where the outcomes of multiple late-stage trials could determine the company's trajectory for years to come. With programs advancing in generalized anxiety disorder, major depressive disorder, and autism spectrum disorder, the next two years represent a critical test of whether its pipeline can deliver on its ambitious promise.

MM120 for Generalized Anxiety Disorder (GAD)

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.